The SnoB study analysed the variability of the integrase (IN) gene of non-B viruses from treatment-na  ve @entity1 to determine whether non-B subtypes carry natural resistance mutations to @entity5197 (RAL). Plasma viral RNA from 427 @entity1 was gained, and IN sequences were subtyped and screened for subtype-specific highly-variable residues. Seven viruses of different subtypes were phenotypically tested for RAL susceptibility; 359/427 samples could be sequenced. One hundred and seventy samples (47%) were classified as non-B subtypes. No primary RAL resistance-associated mutations (RRAMs) were detected. Certain secondary mutations were found, mostly related to specific non-B subtypes. @entity70288 was significantly more prevalent in subtype 02_AG, @entity70289 in A and 06_cpx, @entity25427 in 06_cpx, and @entity62377 in 12_BF. Various additional mutations were also detected and could be associated with the subtype too. While @entity70290 and @entity70291 were correlated with B subtype, @entity70292 , @entity70293 , @entity70294 , @entity70295 , @entity70296 and @entity70297 were more frequent in certain non-B subtypes. The @entity4059 ( @entity4059 ) of 7 viral strains of different subtypes ranged from 1.0 to 1.9. No primary or secondary but subtype-associated additional RRAMs were present. No correlation between @entity4059 and additional RRAMs was found. The prevalence of RRAMs was higher in non-B samples. However, the RFs for the analysed non-B subtypes showed lower values to those reported relevant to clinical failure. As the role of baseline secondary and additional mutations on RAL therapy failure is actually not known, baseline IN screening is necessary.

The SnoB study: frequency of baseline XXXX resistance mutations prevalence in different non-B subtypes.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity70290 :: ('p|SUB|K|156|N', 'ProteinMutation') :: ['K156 N'] @entity70289 :: ('c|SUB|T|97|A', 'DNAMutation') :: ['T97A'] @entity70295 :: ('c|SUB|T|125|A', 'DNAMutation') :: ['T125A'] @entity4059 :: ('MESH:D007020', 'Disease') :: ['RF', 'resistance factors'] @entity70291 :: ('p|SUB|S|230|N', 'ProteinMutation') :: ['S230 N'] @entity70294 :: ('p|SUB|T|112|I', 'ProteinMutation') :: ['T112I'] @entity70292 :: ('p|SUB|V|72|I', 'ProteinMutation') :: ['V72I'] @entity70297 :: ('p|SUB|T|206|S', 'ProteinMutation') :: ['T206S'] @entity62377 :: ('p|SUB|G|163|R', 'ProteinMutation') :: ['G163R'] @entity25427 :: ('p|SUB|V|151|I', 'ProteinMutation') :: ['V151I'] @entity5197 :: ('MESH:C507898', 'Chemical') :: ['raltegravir'] @entity70288 :: ('p|SUB|L|74|M', 'ProteinMutation') :: ['L74 M'] @entity70293 :: ('p|SUB|L|74|I', 'ProteinMutation') :: ['L74I'] @entity70296 :: ('p|SUB|V|201|I', 'ProteinMutation') :: ['V201I']
@entity5197 :: (MESH:C507898,Chemical) :: ['raltegravir']
